Cargando…

Immune profiling and immunotherapeutic targets in pancreatic cancer

BACKGROUND: Immunotherapeutic approaches for pancreatic ductal adenocarcinoma (PDAC) are less successful as compared to many other tumor types. In this study, comprehensive immune profiling was performed in order to identify novel, potentially actionable targets for immunotherapy. METHODS: Formalin-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenzo, Felicia L., Kato, Shumei, Pabla, Sarabjot, DePietro, Paul, Nesline, Mary K., Conroy, Jeffrey M., Burgher, Blake, Glenn, Sean T., Kuvshinoff, Boris, Kurzrock, Razelle, Morrison, Carl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867882/ https://www.ncbi.nlm.nih.gov/pubmed/33569421 http://dx.doi.org/10.21037/atm-20-1076

Ejemplares similares

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
por: Adashek, Jacob J., et al.
Publicado: (2023)

Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy
por: Jou, Jessica, et al.
Publicado: (2023)

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
por: Miyashita, Hirotaka, et al.
Publicado: (2023)

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay
por: Pabla, Sarabjot, et al.
Publicado: (2019)

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
por: George, Saby, et al.
Publicado: (2018)

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors
por: Conroy, Jeffrey M., et al.
Publicado: (2021)

Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
por: Pabla, Sarabjot, et al.
Publicado: (2021)

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
por: Dy, Grace K., et al.
Publicado: (2019)

Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients
por: Zhang, Tian, et al.
Publicado: (2020)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
por: Kato, Shumei, et al.
Publicado: (2020)

Oncologist uptake of comprehensive genomic profile guided targeted therapy
por: Nesline, Mary K., et al.
Publicado: (2019)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
por: Pabla, Sarabjot, et al.
Publicado: (2019)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
por: Paluch, Benjamin E, et al.
Publicado: (2016)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
por: Jardim, Denis L., et al.
Publicado: (2020)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
por: Conroy, Jeffrey M., et al.
Publicado: (2019)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
por: Adashek, Jacob J., et al.
Publicado: (2020)

Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma
por: Mukherjee, Sarbajit, et al.
Publicado: (2021)

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
por: Kato, Shumei, et al.
Publicado: (2018)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population
por: Rosenberg, Shai, et al.
Publicado: (2023)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

Current Immunotherapeutic Approaches in Pancreatic Cancer
por: Koido, Shigeo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_i0lip0od3qs0pjfi7vjo6dnn5c